CD9 Antibody, anti-human, REAfinity™
Synonyms: BA2, MIC3, MRP-1, p24, Tspan29, BTCC-1, DRAP-27, TSPAN-29
RECOMBINANT
Clone:
REA1552 | D3H4P
Type of antibody:
Recombinant antibodies, Primary antibodies
Isotype:
recombinant human IgG1
Applications:
MICS, IF, IHC Glossary
External link icon
Quality Assurance Certified ProductSatisfaction
guaranteed
more »
Select a conjugate:

Related products for CD9 Antibody, anti-human, REAfinity™

Specifications for CD9 Antibody, anti-human, REAfinity™
Overview

Clone REA1552 recognizes CD9, which is a member of the tetraspanin family and organizes membrane-associated protein networks known as tetraspanin-enriched microdomains. It regulates essential cellular processes such as cell adhesion, migration, signal transduction, proliferation, as well as sperm–egg fusion, and interacts with integrins and various membrane proteins. CD9 is widely expressed across many tissues, with particularly high expression in leukocytes (B cells, T cells, NK cells, monocytes, macrophages, dendritic cells) and endothelial cells. It localizes to the plasma membrane and is a characteristic marker of exosomes. CD9 participates in immune regulation, inflammatory processes, infection, tissue repair, and notably in tumor progression. Depending on the cancer type, CD9 can act as either a suppressor or promoter of metastasis. Because of its central role in adhesion, exosome biology, and metastatic behavior, CD9 is considered a promising biomarker and potential therapeutic target.

Alternative names

BA2, MIC3, MRP-1, p24, Tspan29, BTCC-1, DRAP-27, TSPAN-29

Detailed product information

Technical specifications

Clone
REA1552
Clonality
monoclonal
Isotype
recombinant human IgG1
Host
human cell line
Type of antibody
Recombinant antibodies, Primary antibodies
Species reactivity
human
Antigen
CD9
Distribution of antigen
B cells, macrophages, monocytes, NK cells, T cells, dendritic cells, leukocytes, endothelial cells

Recombinant antibodies at Miltenyi Biotec

As an innovation-powered company with a commitment to quality and excellence, Miltenyi Biotec applies cutting-edge methods to discover and develop newer and better antibodies to satisfy both market demand and regulatory requirements.

The Miltenyi way of generating best-in-class antibodies and antibody conjugates

At Miltenyi Biotec, we opt for recombinant antibodies, which enable sequence verification and optimization for lot-to-lot consistency, making them superior to hybridoma-based antibodies.

Infusing our unique expertise

Recombinants are the result of combining genetic material from different immunized animals, and using display technologies to screen in-house antibody libraries for the best antibodies. Additional analyses on existing hybridoma-based antibodies can also give rise to sequences contributing to novel recombinants.

Maximizing value for your research

By further re-engineering these antibody sequences, we can precisely control their properties to achieve the following benefits:

reduce undesirable binding to Fc gamma receptors,

  • eliminate destabilizing amino acid motifs,
  • increase specific bonding affinity for stronger, more accurate targeting, and
  • optimize fluorochrome conjugation for brighter and clearer signals.

In a final step, by synthesizing and cloning the resulting gene sequence, we achieve an expression vector that develops a cell line, which in turn produces a special recombinant antibody.

Better science with quality antibodies

Already in 2015, 100 of the world’s leading scientists collectively called for better standards and reproducibility in antibody production, proposing recombinant antibodies to circumvent variability (Baker, M. Reproducibility crisis: Blame it on the antibodies. Nature 521, 274–276 (2015). https://doi.org/10.1038/521274a). Moreover, by applying reverse engineering, which is encouraged by the EU Directive 2016/943 r, Miltenyi Biotec acts “[i]n the interest of innovation and fostering competition…” (§16).

Resources for CD9 Antibody, anti-human, REAfinity™
Certificates

To access a Certificate of Analysis (CoA) follow the link below and enter the specific lot of your product.

Get certificate

Should you wish to request additional documentation, such as a Safety Data Sheet (SDS) in other languages than English or Swedish, an SDS-replacement document, or a Certificate of Origin (CoO), please direct your inquiry to your local technical support team.

Contact technical support

Citations for CD9 Antibody, anti-human, REAfinity™
Publications
  1. Lorico, A. et al. (2021) CD9, a tetraspanin target for cancer therapy? Exp. Biol. Med. (Maywood) 246 (9): 1121-1138
  2. Umeda, R. et al. (2020) Structural insights into tetraspanin CD9 function. Nat Commun 11 (1): 1606
  3. Brosseau, C. (2018) CD9 Tetraspanin: A New Pathway for the Regulation of Inflammation? Front Immunol 9: 2316